Biblio
Stem cell mutations can be detected in myeloma patients years before onset of secondary leukemias. Blood Adv. 2019;3(23):3962-3967.
TP53 mutations and RNA-binding protein MUSASHI-2 drive resistance to PRMT5-targeted therapy in B-cell lymphoma. Nat Commun. 2022;13(1):5676.